Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Slate Path Capital LP's 9th Largest Position

Slate Path Capital LP decreased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 37.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,491,033 shares of the company's stock after selling 5,177,200 shares during the quarter. Teva Pharmaceutical Industries accounts for about 3.4% of Slate Path Capital LP's investment portfolio, making the stock its 9th largest holding. Slate Path Capital LP owned 0.75% of Teva Pharmaceutical Industries worth $187,142,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in TEVA. Oarsman Capital Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $29,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at about $50,000. Ameliora Wealth Management Ltd. bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $66,000. IFP Advisors Inc increased its position in shares of Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after purchasing an additional 1,960 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its holdings in Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after purchasing an additional 949 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on TEVA. Barclays cut their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday. Finally, Bank of America reduced their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Trading Up 2.9 %

Teva Pharmaceutical Industries stock traded up $0.42 during trading hours on Thursday, reaching $14.71. The company had a trading volume of 8,358,482 shares, compared to its average volume of 9,938,244. The firm has a market cap of $16.68 billion, a price-to-earnings ratio of -10.14, a P/E/G ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company has a 50-day moving average price of $15.26 and a 200 day moving average price of $17.58.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.